Oscar Health, Inc. OSCR shares have gained 14.9% in the past three months, outpacing the broader market. The advance has coincided with rapid membership growth, better medical economics and lower administrative expense ratios.
The next test is execution. Oscar must sustain share gains and underwriting discipline while navigating Affordable Care Act (ACA) market contraction, membership cleanup, seasonality and a valuation that already reflects higher expectations.
Oscar's Share Gains Strengthen the Bull Case
Oscar ended the second quarter of 2026 with 2.96 million members, up 46.2% year over year. That growth came even as broader ACA membership declined about 12%, indicating substantial share capture in a contracting market.
OSCR's Pricing Discipline Lifts Underwriting Quality
Oscar's first-half 2026 medical loss ratio improved to 75% from 83% a year earlier. Management attributed the improvement to disciplined pricing, stronger current-year performance and favorable prior-period reserve development.
That mix matters because membership growth is more valuable when medical costs remain controlled. Oscar expects a full-year 2026 medical loss ratio of 81%-82%, implying a higher second-half cadence but still reflecting better economics than the prior-year first half.
Oscar's Tech Leverage Adds Margin Support
The first-half selling, general and administrative ratio fell to 14.7% from 17.2%. Fixed-cost leverage, disciplined expense management and technology-driven efficiencies helped expenses grow more slowly than the membership base.
Oscar also reported 98.7% first-pass claims accuracy, with most claims processed in under 48 hours. Artificial intelligence initiatives across benefits, billing, claims, clinical care and member support could add further scalability without proportionate headcount growth.
The Zacks Consensus Estimate for 2026 and 2027 EPS represents an increase of 208.3% and 21% respectively.
Image Source: Zacks Investment Research
Oscar's Ratings Back Growth but Momentum Is Mixed
The three-month advance can continue if Oscar converts share gains into durable underwriting and operating leverage.
Oscar currently carries a Zacks Rank #1 (Strong Buy), which reflects favorable near-term earnings-estimate revision trends. It also has a VGM Score of A, Growth Score of A and Value Score of B, all favorable readings under the Style Score framework.
The Momentum Score of C is less supportive than an A or B and tempers the picture after the recent price gain. Continued fundamental execution therefore remains important even with a top Zacks Rank and favorable overall Style Scores.
Other Stocks to Consider
Elevance Health, Inc. ELV and UnitedHealth Group UNH are two other top-ranked stocks. Both carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for 2026 earnings of Elevance Health has moved north in the last 30 days while that for UnitedHealth witnessed no movement in the same time frame.
In terms of share price movement, Elevance Health and UnitedHealth Group have lost 1.1% and 11%, respectively, in the past three months.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Oscar Health, Inc. (OSCR): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Elevance Health, Inc. (ELV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).